• Publications
  • Influence
Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor
Preclinical and clinical trial data indicate that rivaroxaban has predictable pharmacokinetics and pharmacodynamics, which are features that differentiate it from oral vitamin K antagonists.
Iterative stereospecific reagent-controlled homologation using a functionalized α-chloroalkyllithium: synthesis of cyclic targets related to epibatidine.
Enantioenriched 1-chloro-2-(1,3-dioxolan-2-yl)ethyllithium was generated by PhLi initiated sulfoxide-ligand exchange and deployed in situ for sequential double stereospecific reagent-controlled
Spontaneous symmetry breaking during interrupted crystallization of an axially chiral amino acid derivative.
High net enantiomeric excess was observed for crystal collections obtained by crystallization of the TFA salt of a configurationally stable yet racemic axially chiral amidoamine in EtOH solution with
Investigation of functionalized α-chloroalkyllithiums for a stereospecific reagent-controlled homologation approach to the analgesic alkaloid (-)-epibatidine.
Four putative functionalized α-chloroakyllithiums RCH2CHLiCl were generated in situ by sulfoxide-lithium exchange from α- chlorosulfoxides, and investigated for the stereospecific reagent-controlled homologation (StReCH) of phenethyl and 2-chloropyrid-5-yl (17) pinacol boronic esters.
Thieme Chemistry Journal Awardees - WhereAre They Now? Stereoselective Synthesis of Z-Configured α,β-UnsaturatedMacrocyclic Lactones and Diolides by Intramolecular Julia-KocienskiOlefination
ω-Sulfonyl aldehydes derived from the esterification of (benzothiazol-2-ylsultonyl)acetic acid with either ω-alkenols or α,ω-diols, followed by ozonolysis or Dess―Martin oxidation as appropriate,
Economic Impact of Implementing Pneumonia Treatment Guidelines for Intravenous to Oral Conversion
Implementing pneumonia treatment guidelines was associated with decreased length of stay and, thus, a decrease in the costs associated with treating pneumonia in an institutional setting, and the VANYHHS could save nearly $300,000 annually as a result of the implementation of the treatment guidelines.
Clostridium difficile—Associated Diarrhea, an Emerging Epidemic: Therapeutic Options
There is a need for novel pharmacologic agents and a thorough review of currently available agents that may have activity against C difficile to outline the appropriate management of CDAD.
The Administration of rt-PA (Activase®) for the Treatment of Empyema in an Adult Patient
It is concluded that intrapleural administration of recombinant tissue plasminogen activator in conjunction with antibiotic therapy for the treatment of empyema in this patient resulted in increased chest tube drainage and provided complete resolution of all signs and symptoms of his infection.
Ramoplanin: A Promising Treatment Option for Clostridium difficile -Associated Diarrhea and Vancomycin-Resistant Enterococcus
Treatment of CDAD with proven efficacy is limited to oral formulations of metronidazole and vancomycin, while ramoplanin, a novel nonabsorbed, glycolipo-depsipeptide antibiotic that has shown activity in vitro and in vivo against VRE and C. difficile, is recommended as the drug of choice.